文献速递艾滋病与性传播感染

HIV-1 Gag突变单独足以在增效PI治疗病毒学失败时降低达芦那韦敏感性

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

研究从520例接受洛匹那韦/利托那韦或达芦那韦/利托那韦单药治疗的HIV感染者中回顾性识别9例病毒学失败患者,测序Gag-蛋白酶区并构建克隆病毒。所有患者携带Gag多态性但无蛋白酶耐药突变,VESPA识别K95R和R286K为失败时Gag特征性突变(P<0.01)。4例克隆分析中1例发现高复制能力且达芦那韦敏感性降低8-13倍的克隆变异,携带K95R、R286K及额外Gag突变,低敏感性依赖Gag序列背景。结论:Gag突变可在无蛋白酶突变时降低达芦那韦敏感性并保持病毒适应性。

要点

  • 增效PI病毒学失败者可仅有Gag突变而无蛋白酶耐药突变。
  • K95R和R286K为病毒学失败时Gag特征性突变(P<0.01)。
  • Gag突变可降低达芦那韦敏感性8-13倍且保持复制能力。

核心结论

  • Gag突变可在无蛋白酶突变时降低达芦那韦敏感性并保持病毒适应性,此效应依赖Gag序列背景,可发生于增效PI治疗失败时。

研究设计与样本

  • 回顾性队列研究,从520例接受洛匹那韦/利托那韦或达芦那韦/利托那韦单药治疗的HIV感染者中识别9例病毒学失败患者,测序HIV-1 Gag-蛋白酶区并构建克隆病毒进行表型分析。

主要发现

  • 所有分析患者均携带Gag相关多态性,无蛋白酶基因耐药突变,多数Gag改变位于切割位点之外。
  • VESPA分析识别K95R和R286K为病毒学失败时Gag特征性突变(P<0.01)。
  • 4例可克隆分析患者中1例检出高复制能力且达芦那韦敏感性降低8-13倍的克隆变异,携带K95R、R286K及额外Gag突变。
  • 低达芦那韦敏感性依赖Gag序列背景,其他克隆变异均保持药物敏感性和病毒复制能力。

临床怎么用

  • 增效PI治疗病毒学失败时除蛋白酶基因外应关注Gag区突变,尤其K95R和R286K。
  • Gag突变所致达芦那韦敏感性降低依赖序列背景,需结合表型或克隆分析综合判断。

局限性

  • 回顾性研究,仅9例病毒学失败患者,克隆分析仅4例,样本量小。
  • Gag突变降低达芦那韦敏感性的机制及临床影响需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. METHODS: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region. RESULTS: All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity. CONCLUSIONS: Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Blanch-Lombarte O, Santos JR, Peña R, et al. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy. J Antimicrob Chemother. 2020. PMID: 32556165. doi:10.1093/jac/dkaa228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。